GSK3β promotes the proteasomal degradation of β-catenin and then causes cell apoptosis, whereas GSK3β inhibition up-regulates the expression of β-catenin and exerts neuroprotective effects in models of PD [63–65]. This evidence concerns the gene GSK3B and Parkinson disease.